Human/Machine Interface: What the HeartMate 3 ® Device Tells Us About the Future

Recruiting Observational Study
LVAD Frailty GI Bleed Right Heart Failure Infections Hypertension Arrhythmias Stroke
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 100
Sex
Any
Study type
Observational
Participants needed
150 (estimated)
Sponsor
International Consortium of Circulatory Assist Clinicians · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Durable left ventricular assist devices (dLVAD) have been increasingly utilized since the mid to late 1990s, with an uptick of utility starting in 2010 following expanded indications for therapy to not only include a bridge to transplantation strategy, but also for those individuals who suffer from advanced heart failure (HF) and do not qualify for cardiac transplantation. Despite the decreasing s…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * 18 years of age or older * Scheduled Heartmate 3 ® dLVAD implantation Exclusion Criteria: * \<18 years of age * Scheduled for dLVAD that is NOT a Heartmate 3 (R) device
Contacts

Sarah E Schroeder, PhD MSN RN

402-937-3595

sarah.schroeder@vadcoordinator.org

CONTACT

Thomas Schloglhofer, MSc

+43 650 7119129

thomas.schloeglhofer@meduniwien.ac.at

CONTACT